• Home
• Responsibility
• CR Report 2005
• Report index
• Site map

Site map

• CR Report 2005
• Summary and highlights
• CEO/Chairman statement
• About this report
• Managing CR
  • Why CR is important to GSK
  • Our CR principles
  • Stakeholder engagement
    • Stakeholder feedback
      • Stakeholder feedback
      • How we are responding
    • How we are responding
  • Government and external affairs
    • Membership of trade associations
    • Political donations
    • US lobbying expenditure
    • Policy positions
    • Patient advocacy
      • Principles for working with patient groups
• Access to medicines
  • Developing world
    • Research and development
    • Preferential pricing
      • Eligibility for not-for-profit prices
    • Voluntary licensing and partnerships
    • Major public health initiatives
  • Developed world
• Research
  • Animal research
  • Conduct of clinical trials
  • Training and auditing for clinical trials
  • Clinical trial information and results
• Ethical conduct
  • Code of conduct
  • Marketing ethics
    • Marketing codes of practice
    • Consumer advertising
  • Training and awareness
  • Monitoring and compliance
• Employees
  • Employee surveys
  • Diversity
  • Employee development and talent management
  • Internal communication
  • Health and safety
    • How we manage health and safety
    • Injury and illness (rates and causes)
    • Serious incidents and fatalities
    • Employee health
    • Safety programmes
• Human rights
  • Employees
  • Suppliers
    • Human rights clause
• Environment
  • Verification
  • Environmental management
    • Plan for excellence
    • Audits and certification
    • Stakeholder engagement
    • Training and awareness
    • EHS excellence award
  • Progress towards targets
  • Materials efficiency
  • Product stewardship
    • Product design
    • Pharmaceuticals in the environment
    • Metered Dose Inhalers
  • Energy and global warming potential
    • Energy consumption
    • Transport
  • Water
    • Water use
    • Wastewater
  • Waste
    • Hazardous waste
    • Non-hazardous waste
    • Recycling
    • Non-routine waste
  • Ozone depletion
    • ODS in manufacturing
    • ODS in ancillary equipment
  • Volatile organic compounds
  • Biodiversity
  • Suppliers
• Community investment
  • Value of community investment
  • Humanitarian relief
  • Community partnerships
  • Supporting education
  • Employee involvement
• Data summary
• Case studies
• PDF downloads
• Report index
  • Site map
  • GRI index
    • Economic indicators
    • Environmental indicators
    • Social indicators
• Feedback